|
|
5 Golda Meir St, Weizmann Science Park, P.O.Box 4052
Nes Ziona, 74140 Israel
phone:972-8-9465142
fax:972-8-9465502
|
|
| Symbol |
Private |
| Founded |
1996 |
| Employees |
30 |
|
|
| www.orsense.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Non-invasive Measurement of Critical Blood Parameters and Blood Glucose Levels |
|
| Management |
| Hamutal Anavi Russo, Chief Financial Officer; Dr. Ephraim Carlebach, Vice President Patient Monitoring; Alexander Finarov, Vice President Engineering; Ephraim Gabis, Vice President Operations; Hillegonda "Honny" Kipnis Groen, Vice President Sales (Europe); Aharon Weinstein, Vice President Research |
| |
|
|
| |
|
| Keywords |
| Glucose, diabetes, insulin, medical devices |
|
|
|
| Description |
|
OrSense is a medical device company that develops and commercializes patient monitoring solutions for non-invasive continuous measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense are led by Israel Health Care Ventures and STAR Ventures, two of Israels leading venture capital firms. |
|
| Products / Services |
OrSense's flagship product is the CE approved NBM-200MP, which monitors and displays oxygen saturation of Hb (SpO2), low signal oximetry, SpO2, pulse rate, plethysmogram and hemoglobin, all non-invasively and continuously. The system is designed for use in hospitals including operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services. OrSense's next generation products target non-invasive monitoring of blood glucose in the hospital and for home use. The CE approved glucose monitor was tested on over 450 diabetic subjects. Results indicate performance similar to those of invasive glucose sensors on the market today.
|
|
| Technology / Differentiation |
| OrSenses patented technology, known as Occlusion Spectroscopy, uses a non-invasive optical measurement platform combined with a finger attached ring-shaped sensor probe. The pressure applied by the sensor temporarily occludes the blood flow in the finger, creating new blood dynamics which generate a unique, strong optical signal, yielding a high signal-to-noise ratio that is wholly blood specific. Analysis of the signal provides the sensitivity necessary to measure glucose, hemoglobin, oxymetry (under severe low perfusion levels), pulse-rate, and other analytic concentrations. This breakthrough technology enables a generation of transmission signal across the finger which overcomes the key technological barrier related to the low signal to noise ratio, due to poor or compromised peripheral perfusion , interferences from motion induced noise and other artifacts. |
|
| Market / Customers |
OrSense products target the hospital and home care markets. The hospital market, focused on acute and sub acute care departments, has an annual potential of over $3 billion. The home care market has a potential of close to $10 billion.
|
|
| Status |
| OrSense's CE approved NBM-200MP is marketed in hospitals in Europe and Israel.
OrSenses intellectual property portfolio consists of 51 granted patents with over 20 additional applications in process. The company is currently seeking: venture capital, institutional investor awareness, M&A advisors, and strategic/corporate partners. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members